Trial · NCT07889453
Metabolic Effects of Switching From Injectable Semaglutide to Tirzepatide
NCT07889453, Active not recruiting, LMC Diabetes & Endocrinology Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Metabolic Effects of Switching From Injectable Semaglutide to Tirzepatide. Trials, record NCT07889453. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07889453
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Metabolic Effects of Switching From Injectable Semaglutide to Tirzepatide
- NCT number
- NCT07889453
- Status
- Active not recruiting
- Enrollment
- 650 participants, estimated
- Lead sponsor
- LMC Diabetes & Endocrinology Ltd.
- Conditions
- Obesity, Type 2 Diabetes (T2D)
- Interventions
- Tirzepatide
- First posted
- 2026-10-22
- Last updated
- 2026-10-22
Source ClinicalTrials.gov
Registered outcomes31
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from Baseline in Body Weight at 12 Months - T2D Switch TZP Cohort | Baseline to follow-up (6-12 months) | Change in body weight (kg) at 6-12-month follow-up (closest observation to 12 month follow-up, ±6 weeks) compared to baseline (closest observation to the index date, ±6 weeks) among individuals living with T2D who switched from injectable semaglutide to tirzepatide during the index period. |
| Primary | Change from Baseline in Body Weight at 12 Months - Obesity Switch TZP Cohort | Baseline to follow-up (6-12 months) | Change in body weight (kg) at 6-12-month follow-up (closest observation to 12 month follow-up, ±6 weeks) compared to baseline (closest observation to the index date, ±6 weeks) among individuals living with obesity (non-diabetes) who switched from injectable semaglutide to tirzepatide during the index period. |
| Secondary | Change from Baseline in HbA1c at 12 Months - T2D Cohort | Baseline to follow-up (6-12 months) | Change in HbA1c among individuals living with T2D who switched from injectable semaglutide to tirzepatide and a propensity score-matched group of individuals living with T2D maintaining semaglutide |
| Secondary | Change from Baseline in Percent Body Weight at 12 Months - T2D Cohort | Baseline to follow-up (6-12 months) | Change in percent body weight (%) among individuals living with T2D who switched from injectable semaglutide to tirzepatide and a propensity score-matched group of individuals living with T2D maintaining semaglutide |
| Secondary | Change from Baseline in Body Mass Index (BMI) at 12 Months - T2D Cohort | Baseline to follow-up (6-12 months) | Change in BMI (kg/m\^2) among individuals living with T2D who switched from injectable semaglutide to tirzepatide and a propensity score-matched group of individuals living with T2D maintaining semaglutide |
| Secondary | Change from Baseline in Blood Pressure at 12 Months - T2D Cohort | Baseline to follow-up (6-12 months) | Change in blood pressure (mmHg) among individuals living with T2D who switched from injectable semaglutide to tirzepatide and a propensity score-matched group of individuals living with T2D maintaining semaglutide |
| Secondary | Change from Baseline in Waist Circumference at 12 Months - T2D Cohort | Baseline to follow-up (6-12 months) | Change in waist circumference (cm) among individuals living with T2D who switched from injectable semaglutide to tirzepatide and a propensity score-matched group of individuals living with T2D maintaining semaglutide |
| Secondary | Change from Baseline in Estimated Glomerular Filtration Rate (eGFR) at 12 Months - T2D Cohort | Baseline to follow-up (6-12 months) | Change in eGFR (ml/min/1.73m\^2) among individuals living with T2D who switched from injectable semaglutide to tirzepatide and a propensity score-matched group of individuals living with T2D maintaining semaglutide |
| Secondary | Change from Baseline in Urine Albumin-to-Creatinine Ratio (uACR) at 12 Months - T2D Cohort | Baseline to follow-up (6-12 months) | Change in uACR (mg/mmol) among individuals living with T2D who switched from injectable semaglutide to tirzepatide and a propensity score-matched group of individuals living with T2D maintaining semaglutide |
| Secondary | Change from Baseline in Alanine Transaminase (ALT) at 12 Months - T2D Cohort | Baseline to follow-up (6-12 months) | Change in ALT (U/L) among individuals living with T2D who switched from injectable semaglutide to tirzepatide and a propensity score-matched group of individuals living with T2D maintaining semaglutide |
1 to 10 of 31Source ClinicalTrials.gov
See all 31 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07889453
GET https://conductscience.org/api/trials/v1/NCT07889453/registered?page=2